MX2022005898A - Inhibidores de cinasa dependiente de ciclina 7 (cdk7). - Google Patents
Inhibidores de cinasa dependiente de ciclina 7 (cdk7).Info
- Publication number
- MX2022005898A MX2022005898A MX2022005898A MX2022005898A MX2022005898A MX 2022005898 A MX2022005898 A MX 2022005898A MX 2022005898 A MX2022005898 A MX 2022005898A MX 2022005898 A MX2022005898 A MX 2022005898A MX 2022005898 A MX2022005898 A MX 2022005898A
- Authority
- MX
- Mexico
- Prior art keywords
- subject
- diseases
- cdk7
- cyclin
- compositions
- Prior art date
Links
- 102000016736 Cyclin Human genes 0.000 title 1
- 108050006400 Cyclin Proteins 0.000 title 1
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 101150059448 cdk7 gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 abstract 2
- 101710106276 Cyclin-dependent kinase 7 Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000011594 Autoinflammatory disease Diseases 0.000 abstract 1
- 206010060999 Benign neoplasm Diseases 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La presente invención proporciona nuevos compuestos de la Fórmula (I) y sales, solvatos, hidratos, tautómeros, estereoisómeros, derivados etiquetados isotópicamente y composiciones farmacéuticamente aceptables de los mismos. También se proporcionan métodos y kits que incluyen los compuestos o composiciones para tratar o prevenir enfermedades proliferativas (por ejemplo, cánceres (por ejemplo, leucemia, melanoma, mieloma múltiple), neoplasias benignas, angiogénesis, enfermedades inflamatorias, enfermedades autoinflamatorias y enfermedades autoinmunes) en un sujeto. El tratamiento de un sujeto con una enfermedad proliferativa usando un compuesto o composición de la invención puede inhibir la actividad aberrante de la cinasa dependiente de ciclina 7 (CDK7) y, por lo tanto, inducir la apoptosis celular y/o inhibir la transcripción en el sujeto.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662361852P | 2016-07-13 | 2016-07-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022005898A true MX2022005898A (es) | 2022-06-27 |
Family
ID=59501528
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000527A MX392308B (es) | 2016-07-13 | 2017-07-13 | Inhibidores de cinasa dependiente de ciclina 7 (cdk7). |
| MX2022005898A MX2022005898A (es) | 2016-07-13 | 2019-01-11 | Inhibidores de cinasa dependiente de ciclina 7 (cdk7). |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000527A MX392308B (es) | 2016-07-13 | 2017-07-13 | Inhibidores de cinasa dependiente de ciclina 7 (cdk7). |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20230062491A1 (es) |
| EP (2) | EP3484871B1 (es) |
| JP (2) | JP7058636B2 (es) |
| KR (1) | KR102587758B1 (es) |
| CN (1) | CN110036004A (es) |
| AU (2) | AU2017295863B2 (es) |
| BR (1) | BR112019000716A2 (es) |
| CA (1) | CA3030795A1 (es) |
| ES (1) | ES2954278T3 (es) |
| IL (2) | IL264222B (es) |
| MX (2) | MX392308B (es) |
| RU (1) | RU2019103870A (es) |
| SG (2) | SG11201900328WA (es) |
| WO (1) | WO2018013867A1 (es) |
| ZA (2) | ZA201900874B (es) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10913983B2 (en) | 2017-07-18 | 2021-02-09 | University Of South Carolina | Sensitivity markers and uses for CDK7 inhibitors in breast cancers |
| AU2019209470A1 (en) * | 2018-01-16 | 2020-08-13 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| AU2019209475A1 (en) * | 2018-01-16 | 2020-08-20 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| LT3784664T (lt) * | 2018-04-26 | 2025-03-25 | Pfizer Inc. | 2-amino-piridino arba 2-amino piridino dariniai kaip nuo ciklino priklausomos kinazės inhibitoriai |
| JP2021151955A (ja) * | 2018-05-22 | 2021-09-30 | 株式会社カネカ | 光学活性−ｃｉｓ−アミノピペリジンの製造方法 |
| CN109206427A (zh) * | 2018-09-25 | 2019-01-15 | 安徽医科大学 | 芳香杂环乙烯基吡唑并嘧啶类化合物、药物制剂及制备方法与应用 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| CN113677346A (zh) * | 2018-11-01 | 2021-11-19 | 希洛斯医药品股份有限公司 | 周期蛋白依赖性激酶7(cdk7)的抑制剂 |
| TWI835909B (zh) * | 2018-11-01 | 2024-03-21 | 美商錫羅斯製藥公司 | 週期素依賴性激酶7(cdk7)之抑制劑 |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| EP3958861A4 (en) * | 2019-04-23 | 2023-05-03 | Dana-Farber Cancer Institute, Inc. | DEGRADERS OF CYCLIN DEPENDENT KINASE 12 (CDK12) AND USES THEREOF |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| CA3150681A1 (en) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| CN112430208A (zh) * | 2019-08-26 | 2021-03-02 | 东莞市东阳光仿制药研发有限公司 | 一种pf-06651600中间体的制备方法 |
| WO2021072232A1 (en) | 2019-10-11 | 2021-04-15 | Incyte Corporation | Bicyclic amines as cdk2 inhibitors |
| WO2021087138A1 (en) * | 2019-10-29 | 2021-05-06 | Syros Pharmaceuticals, Inc. | Methods of treating cancer in biomarker-identified patients with inhibitors of cyclin-dependent kinase 7 (cdk7) |
| CN111393415B (zh) * | 2020-04-30 | 2020-11-20 | 苏州信诺维医药科技有限公司 | 一种杂芳腈类化合物及其应用 |
| EP4157465A2 (en) * | 2020-05-29 | 2023-04-05 | Syros Pharmaceuticals, Inc. | Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9 |
| CN111675708A (zh) * | 2020-06-10 | 2020-09-18 | 南京合巨药业有限公司 | 一种6-氰基-7-氮杂吲哚及其衍生物的制备方法 |
| CN112661745A (zh) * | 2020-07-24 | 2021-04-16 | 浙江同源康医药股份有限公司 | 用作cdk7激酶抑制剂的化合物及其应用 |
| CN114133394B (zh) * | 2020-08-12 | 2023-12-08 | 赛诺哈勃药业（成都）有限公司 | 一种选择性针对细胞周期依赖性激酶12活性的化合物、制备方法及医药用途 |
| DK4214202T3 (da) * | 2020-09-15 | 2025-03-31 | Pfizer | Faste former af en cdk4-hæmmer |
| WO2022063212A1 (zh) * | 2020-09-24 | 2022-03-31 | 广州费米子科技有限责任公司 | 嘧啶基衍生物、其制备方法及其用途 |
| WO2022089444A1 (zh) * | 2020-10-28 | 2022-05-05 | 恒元生物医药科技(苏州)有限公司 | 一种含氮杂环化合物及其应用 |
| MX2023007446A (es) * | 2020-12-24 | 2023-09-19 | Gt Apeiron Therapeutics Ltd | Compuesto heterociclico aromatico, composicion farmaceutica y uso de estos. |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| WO2023049691A1 (en) * | 2021-09-23 | 2023-03-30 | Zeno Management, Inc. | Cdk7 inhibitors and methods of treating cancer |
| CN116082312A (zh) * | 2021-11-05 | 2023-05-09 | 浙江同源康医药股份有限公司 | 用作cdk7激酶抑制剂的化合物及其应用 |
| WO2023091726A1 (en) * | 2021-11-18 | 2023-05-25 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin‑dependent kinase 12 (cdk12) |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| TW202340211A (zh) * | 2021-12-22 | 2023-10-16 | 香港商英矽智能科技知識產權有限公司 | 嘧啶雜環化合物、其製法與醫藥上的用途 |
| CN118339157A (zh) * | 2021-12-24 | 2024-07-12 | 江苏恒瑞医药股份有限公司 | 氢化吲哚类化合物、其制备方法及其在医药上的应用 |
| EP4242195A1 (en) * | 2022-03-09 | 2023-09-13 | EuroChem Antwerpen | Use of pyrazolo[3,4-b]pyridine compounds as nitrification inhibitor |
| AU2023249795A1 (en) | 2022-04-08 | 2024-10-17 | Shy Therapeutics, Llc | Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| CN117384135A (zh) * | 2022-07-04 | 2024-01-12 | 浙江同源康医药股份有限公司 | 用作cdk7激酶抑制剂的化合物及其应用 |
| WO2024007985A1 (zh) * | 2022-07-08 | 2024-01-11 | 成都苑东生物制药股份有限公司 | 一种嘧啶类衍生物、其制备方法及用途 |
| WO2024088296A1 (zh) | 2022-10-25 | 2024-05-02 | 上海拓界生物医药科技有限公司 | 哌啶并嘧啶类衍生物、其制备方法及其在医药上的应用 |
| EP4628488A4 (en) * | 2022-12-16 | 2026-01-21 | Adlai Nortye Biopharma Co Ltd | CYCLINE K DEGRADING AGENT AND ITS USE |
| CN115819406B (zh) * | 2023-02-24 | 2023-06-02 | 淄博百极荣创医药科技有限公司 | 3-(4-嘧啶)-1h-吲哚类化合物的合成方法 |
| CN116082337B (zh) * | 2023-03-16 | 2023-06-23 | 英矽智能科技(上海)有限公司 | 炔基取代的杂环化合物，其制法与医药上的用途 |
| WO2024255845A1 (zh) * | 2023-06-14 | 2024-12-19 | 中国科学院上海药物研究所 | 一类蛋白降解剂及其药物组合物和用途 |
| WO2024260325A1 (zh) * | 2023-06-19 | 2024-12-26 | 英矽智能科技知识产权有限公司 | 大环类化合物的合成及其在医药上的用途 |
| WO2026021534A1 (zh) * | 2024-07-25 | 2026-01-29 | 浙江同源康医药股份有限公司 | 一种嘧啶类衍生物的固体形式及其制备方法和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9604311D0 (en) | 1996-02-29 | 1996-05-01 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase |
| WO2006038001A1 (en) * | 2004-10-06 | 2006-04-13 | Celltech R & D Limited | Aminopyrimidine derivatives as jnk inhibitors |
| CA2608072A1 (en) | 2005-05-24 | 2006-11-30 | Astrazeneca Ab | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity |
| AU2011239966B2 (en) | 2010-04-16 | 2014-05-08 | Ac Immune S.A. | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins |
| MX2013006467A (es) * | 2010-12-09 | 2013-10-01 | Amgen Inc | Compuestos biciclicos como inhibidores pim. |
| WO2012110773A1 (en) | 2011-02-17 | 2012-08-23 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
| CN103664743B (zh) | 2012-09-12 | 2016-09-14 | 上海药明康德新药开发有限公司 | (3s, 4r)-3-胺基-4-甲基哌啶-1-羧酸叔丁酯的制备方法 |
| MX2015009952A (es) | 2013-02-08 | 2015-10-05 | Celgene Avilomics Res Inc | Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos. |
| EP3057954A2 (en) * | 2013-10-18 | 2016-08-24 | Syros Pharmaceuticals, Inc. | Heteromaromatic compounds useful for the treatment of proliferative diseases |
| WO2015058126A1 (en) * | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
| HRP20190039T1 (hr) * | 2014-04-04 | 2019-03-08 | Syros Pharmaceuticals, Inc. | Inhibitori ciklin-ovisne kinaze 7 (cdk7) |
| AU2019209470A1 (en) * | 2018-01-16 | 2020-08-13 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| CN113677346A (zh) * | 2018-11-01 | 2021-11-19 | 希洛斯医药品股份有限公司 | 周期蛋白依赖性激酶7(cdk7)的抑制剂 |
-
2017
- 2017-07-13 SG SG11201900328WA patent/SG11201900328WA/en unknown
- 2017-07-13 JP JP2019502013A patent/JP7058636B2/ja active Active
- 2017-07-13 ES ES17746235T patent/ES2954278T3/es active Active
- 2017-07-13 MX MX2019000527A patent/MX392308B/es unknown
- 2017-07-13 CA CA3030795A patent/CA3030795A1/en active Pending
- 2017-07-13 EP EP17746235.5A patent/EP3484871B1/en active Active
- 2017-07-13 AU AU2017295863A patent/AU2017295863B2/en active Active
- 2017-07-13 BR BR112019000716A patent/BR112019000716A2/pt not_active Application Discontinuation
- 2017-07-13 EP EP23177402.7A patent/EP4295852A3/en not_active Withdrawn
- 2017-07-13 KR KR1020197004222A patent/KR102587758B1/ko active Active
- 2017-07-13 SG SG10202012466PA patent/SG10202012466PA/en unknown
- 2017-07-13 WO PCT/US2017/042017 patent/WO2018013867A1/en not_active Ceased
- 2017-07-13 RU RU2019103870A patent/RU2019103870A/ru unknown
- 2017-07-13 CN CN201780057760.8A patent/CN110036004A/zh active Pending
-
2019
- 2019-01-11 MX MX2022005898A patent/MX2022005898A/es unknown
- 2019-01-13 IL IL264222A patent/IL264222B/en unknown
- 2019-02-11 ZA ZA2019/00874A patent/ZA201900874B/en unknown
-
2021
- 2021-11-25 JP JP2021191517A patent/JP7460593B2/ja active Active
-
2022
- 2022-02-08 US US17/667,288 patent/US20230062491A1/en not_active Abandoned
- 2022-04-24 IL IL292422A patent/IL292422A/en unknown
- 2022-10-06 AU AU2022246416A patent/AU2022246416C1/en active Active
-
2023
- 2023-02-10 ZA ZA2023/01672A patent/ZA202301672B/en unknown
-
2024
- 2024-04-15 US US18/635,402 patent/US20240360165A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202301672B (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| PH12016501935A1 (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| WO2015058163A3 (en) | Heteromaromatic compounds useful for the treatment of prolferative diseases | |
| WO2015058126A8 (en) | Heteroaromatic compounds useful for the treatment of prolferative diseases | |
| HK1245260A1 (zh) | 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂 | |
| HK1246645A1 (zh) | 细胞周期蛋白依赖性激酶的抑制剂 | |
| WO2017044858A3 (en) | Inhibitors of cyclin-dependent kinases | |
| ZA202102999B (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| HK1254469A1 (zh) | 稠合双环嘧啶衍生物及其用途 | |
| MX2020005363A (es) | Compuestos heterociclicos como inhibidores de prmt5. | |
| PH12020551717A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| PH12020551464A1 (en) | Cd73 inhibitors | |
| WO2020097400A8 (en) | Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof | |
| GEP20227433B (en) | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors | |
| NZ752250A (en) | Compounds, devices, and uses thereof | |
| PH12019502138A1 (en) | Compounds and compositions for treating hematological disorders | |
| PH12020550457A1 (en) | Compounds and compositions for treating hematological disorders | |
| MX2021014531A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| MY201397A (en) | Primidinones as factor xia inhibitors | |
| MX2016009403A (es) | Compuestos heterociclicos. | |
| WO2014063054A8 (en) | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof | |
| MX2020010942A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| MX393711B (es) | Derivados de tiocarbamato como inhibidores de a2a y metodos para su uso en el tratamiento de canceres | |
| PH12020551343A1 (en) | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer | |
| CO2019002171A2 (es) | Compuestos 8-(azetidín-1-il)-[1,2,4]triazolo[1,5-a]piridinilo, composiciones y métodos de utilización de los mismos. |